EUR 3.24
(2.37%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 120.18 Million EUR | 77.46% |
2022 | 69.28 Million EUR | 23.05% |
2021 | 56.3 Million EUR | 87.14% |
2020 | 30.09 Million EUR | -16.91% |
2019 | 36.21 Million EUR | -0.55% |
2018 | 36.41 Million EUR | 34.93% |
2017 | 26.98 Million EUR | 25.55% |
2016 | 21.49 Million EUR | 8.84% |
2015 | 19.74 Million EUR | 17.91% |
2014 | 16.75 Million EUR | 7.85% |
2013 | 15.53 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 54.98 Million EUR | 0.0% |
2023 Q2 | 60.06 Million EUR | 0.0% |
2023 FY | 122.95 Million EUR | 77.46% |
2023 Q4 | 63.68 Million EUR | 0.0% |
2022 Q4 | 39.42 Million EUR | 0.0% |
2022 Q2 | 35.88 Million EUR | 0.0% |
2022 FY | 69.28 Million EUR | 23.05% |
2021 Q2 | 13.73 Million EUR | 37.15% |
2021 Q1 | 10.01 Million EUR | -35.11% |
2021 FY | 56.3 Million EUR | 87.14% |
2021 Q4 | 34.28 Million EUR | 0.0% |
2020 FY | 30.09 Million EUR | -16.91% |
2020 Q1 | 6.89 Million EUR | -58.07% |
2020 Q2 | 8.93 Million EUR | 29.63% |
2020 Q4 | 15.43 Million EUR | 0.0% |
2019 FY | 36.21 Million EUR | -0.55% |
2019 Q4 | 16.43 Million EUR | 0.0% |
2019 Q2 | 22.29 Million EUR | 4660.7% |
2019 Q1 | 468.25 Thousand EUR | -97.61% |
2018 Q4 | 19.56 Million EUR | 0.0% |
2018 FY | 36.41 Million EUR | 34.93% |
2018 Q2 | 19.85 Million EUR | 1510.95% |
2018 Q1 | 1.23 Million EUR | -91.98% |
2017 FY | 26.98 Million EUR | 25.55% |
2017 Q1 | 265.95 Thousand EUR | -98.01% |
2017 Q2 | 15.93 Million EUR | 5892.91% |
2017 Q4 | 15.36 Million EUR | 0.0% |
2016 Q4 | 13.35 Million EUR | 0.0% |
2016 Q2 | 12.71 Million EUR | 7044.98% |
2016 Q1 | 177.94 Thousand EUR | -98.47% |
2016 FY | 21.49 Million EUR | 8.84% |
2015 FY | 19.74 Million EUR | 17.91% |
2015 Q4 | 11.64 Million EUR | 10874.62% |
2015 Q3 | 106.09 Thousand EUR | -99.02% |
2015 Q2 | 10.85 Million EUR | 10133.96% |
2015 Q1 | 106.09 Thousand EUR | 0.0% |
2014 FY | 16.75 Million EUR | 7.85% |
2014 Q2 | 87.69 Thousand EUR | 0.0% |
2014 Q1 | 87.69 Thousand EUR | 0.0% |
2014 Q3 | 87.69 Thousand EUR | 0.0% |
2014 Q4 | 106.09 Thousand EUR | 20.98% |
2013 Q3 | 149.86 Thousand EUR | 0.0% |
2013 Q1 | 149.86 Thousand EUR | 0.0% |
2013 Q4 | 87.69 Thousand EUR | -41.48% |
2013 FY | 15.53 Million EUR | 0.0% |
2013 Q2 | 149.86 Thousand EUR | 0.0% |
2012 Q4 | 149.86 Thousand EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -2777.329% |
ABIVAX Société Anonyme | 127.37 Million EUR | 5.645% |
Adocia SA | 15.62 Million EUR | -668.994% |
Aelis Farma SA | 18.81 Million EUR | -538.642% |
Biophytis S.A. | 14.33 Million EUR | -738.526% |
Advicenne S.A. | 8.21 Million EUR | -1363.007% |
genOway Société anonyme | 16.73 Million EUR | -618.031% |
IntegraGen SA | 5.35 Million EUR | -2145.414% |
Medesis Pharma S.A. | 1.56 Million EUR | -7581.717% |
Neovacs S.A. | 10.34 Million EUR | -1061.942% |
NFL Biosciences SA | 4.37 Million EUR | -2647.515% |
Plant Advanced Technologies SA | 2.76 Million EUR | -4246.927% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -6895.835% |
Sensorion SA | 27.05 Million EUR | -344.25% |
Theranexus Société Anonyme | 3 Million EUR | -3899.551% |
TME Pharma N.V. | 5.49 Million EUR | -2086.393% |
Valbiotis SA | 9.86 Million EUR | -1117.813% |
TheraVet SA | 1.64 Million EUR | -7209.192% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | -491.467% |
DBV Technologies S.A. | 89.4 Million EUR | -34.428% |
Genfit S.A. | 54.8 Million EUR | -119.302% |
GeNeuro SA | 14.35 Million EUR | -737.107% |
Innate Pharma S.A. | 64.57 Million EUR | -86.133% |
MaaT Pharma SA | 21.59 Million EUR | -456.468% |
MedinCell S.A. | 32.92 Million EUR | -265.063% |
Nanobiotix S.A. | 58.92 Million EUR | -103.957% |
OSE Immunotherapeutics SA | 23.58 Million EUR | -409.5% |
Poxel S.A. | 28.76 Million EUR | -317.82% |
GenSight Biologics S.A. | 32.66 Million EUR | -267.991% |
Transgene SA | 31.23 Million EUR | -284.829% |
Valneva SE | 134.92 Million EUR | 10.923% |